Results 81 to 90 of about 16,360 (195)

Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study [PDF]

open access: yes, 2014
OBJECTIVE: To compare the efficacy and safety of intravenous (IV) abatacept, a selective T cell costimulation modulator, versus placebo for the treatment of active class III or IV lupus nephritis, when used on a background of mycophenolate mofetil and ...
Stephanie Meadows‐Shropshire   +29 more
core   +1 more source

Safety and effectiveness of intravenous abatacept for polyarticular-course juvenile idiopathic arthritis: An all-case postmarketing surveillance study

open access: yesPediatric Rheumatology Online Journal
Background In 2018, intravenous abatacept was approved for the treatment of refractory polyarticular-course juvenile idiopathic arthritis (JIA) in Japan.
Tomo Nozawa   +8 more
doaj   +1 more source

Associations of Rheumatoid Arthritis Disease Activity With Frailty Over Five Years of Follow‐up

open access: yesArthritis Care &Research, Volume 78, Issue 11, Page 1759-1768, November 2026.
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis (VARA) registry enrolled from 2003 to 2022 were included.
Courtney N. Loecker   +14 more
wiley   +1 more source

Abatacept in difficult-to-treat juvenile idiopathic arthritis

open access: yes, 2009
Jasmin B Kuemmerle-Deschner1, SM Benseler21Pediatric Rheumatology Clinics, Dept of Pediatrics, University Hospital Tübingen, Germany; 2Dept of Pediatric Rheumatology, The Hospital for Sick Children, Toronto, CanadaAbstract: Juvenile idiopathic ...
SM Benseler, Jasmin B Kuemmerle-Deschner
core  

CD80/86 inhibitors : abatacept

open access: yes, 2016
CD80/CD86 inhibitors are protein constructs which bind and inactivate CD80/CD86 on the surfaces of antigen-presenting B-cells and monocytes, blocking the costimulatory signal between these cells and CD28 on T-cells that is the second message of T-cell ...
Mahler, Stephen M.   +5 more
core   +1 more source

Current treatment options for psoriatic arthritis: spotlight on abatacept

open access: yes, 2018
Francesco Ursini,1,2 Emilio Russo,1 Roberto De Giorgio,3 Giovambattista De Sarro,1 Salvatore D’Angelo4,5 1Department of Health Sciences, University of Catanzaro “Magna Graecia”, Catanzaro, Italy; 2Associazione Calabrese per la Ricerca ...
Russo E   +9 more
core   +2 more sources

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis [PDF]

open access: yes, 2015
Objective: To perform a postmarketing surveillance study evaluating the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis (RA).
Hiroshi Tamada (833630)   +25 more
core   +1 more source

Impact of concomitant methotrexate on disease activity in patients with rheumatoid arthritis tapering abatacept: results from KOBIO registry

open access: yesFrontiers in Medicine
ObjectivesTapering biologic agents can be considered for patients with stable disease activity in rheumatoid arthritis (RA). However, the specific strategy for abatacept is uncertain.
Jun Won Park   +7 more
doaj   +1 more source

Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner

open access: yesArthritis Research & Therapy, 2018
Background The anti-inflammatory effect of abatacept is most pronounced in patients with high-titer autoantibodies (including anticitrullinated protein antibodies [ACPA] and rheumatoid factor [RF]).
Aline Bozec   +5 more
doaj   +1 more source

Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis

open access: yesArthritis Care &Research, Volume 78, Issue 11, Page 1650-1662, November 2026.
Objective Kidney survival is the ultimate goal in lupus nephritis (LN) management, but long‐term predictors remain inadequately studied, requiring long‐term follow‐up. This study aimed to identify baseline and early longitudinal predictors of kidney survival in the Accelerating Medicines Partnership LN longitudinal cohort.
Shangzhu Zhang   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy